# US 2003/0216295 A1 · E-selectin-dependent cell adhesion antagonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0216295 A1
- Document ID: US20030216295A1
- Status: Published application
- Kind: A1
- Application number: 10/325,606
- Filed: 2002-12-20
- Published: 2003-11-20
- Earliest claimed: 1993-06-08
- Assignees: La Jolla Cancer Research Foundation
- Inventors: Minoru Fukuda; Ritsuko Sawada; Shigeru Tsuboi
- Web page: https://patentgrep.com/patent/US20030216295A1

## CPC

- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 14/47: from mammals
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides antagonists to cell adhesion useful in controlling the negative effects of inflammation, and the metastasis of cancer cells. These antagonists are ligands to E-selectin containing the sialyl Lex structure, including sialyl Lex glycoproteins, sialyl Lex glycolipids, and sialyl Lex oligsaccharides, and other related sialyl Lex-containing molecules capable of inhibiting E-selectin mediated cell adhesion to endothelial cells. The present invention also provides antibodies against sialyl Lex determinants capable of interrupting E-selectin mediated cell adhesion, which are also considered antagonists according to the present invention. The present invention also provides methods of using the antagonists of the present invention to reduce inflammation, and methods to inhibit the process of metastasis by carcinogenic cells. The present invention-also provides nucleic acid molecules encoding the glycoprotein antagonists of the present invention, in particular soluble chimeric leukosialin, and vectors capable of expressing these nucleic acid molecules, as well as cells capable of producing sialyl Lex positive recombinant glycoproteins. The present invention further provides a method of determining metastatic potential by comparing the efficiency of E-selectin-mediated adhesion of cell samples. In addition the present invention provides a method of producing a preferred antagonist of the present invention, sialyl Lex positive glycoproteins, in particular, sialy Lex positive chimeric leukosialin.

## Claims

### Claim 1

An antagonist to E-selectin mediated cell adhesion wherein said antagonist is selected from a group of molecules consisting of a ligand to E-selectin containing sialyl Lex-termini, and an anti-sialyl Lex antibody.

### Claim 2 (depends on 1)

The antagonist of claim 1 wherein said ligand is selected from a group of molecules consisting of sialyl Lex-glycoproteins, sialyl Lex-glycolipids, and sialyl Lex-chimeric glycoproteins.

### Claim 3 (depends on 1)

The antagonist of claim 1 wherein said sialyl Lex-containing chimeric glycoprotein is soluble chimeric leukosialin protein.

### Claim 4 (depends on 3)

The antagonist of claim 3, wherein said soluble chimeric leukosialin is chimeric soluble human leukosialin-IgG protein.

### Claim 5 (depends on 1)

A composition containing an effective amount of one or more of the antagonists of claim 1 in addition to a carrier.

### Claim 6

A nucleic acid sequence encoding a soluble chimeric glycoprotein.

### Claim 7

A nucleic acid sequence encoding a soluble chimeric leukosialin-IgG.

### Claim 8 (depends on 6)

A vector containing the nucleic acid sequence of claim 6.

### Claim 9

A mammalian cell containing both a vector capable of directing the expression of a soluble glycoprotein and a vector capable of directing the expression of a fucosyltransferase enzyme which directs sialyl Lex synthesis.

### Claim 10

A mammalian cell containing both a vector capable of directing the expression of a soluble chimeric leukosialin and a vector capable of directing the expression of a fucosyltransferase enzyme which directs sialy Lex synthesis.

### Claim 11 (depends on 9)

The mammalian cell of claim 9 wherein said cell is a CHO cell.

### Claim 12

A method of recombinantly producing glycoproteins expressing sialyl Lex termini comprising transfecting a culture of appropriate mammalian cells with both a vector which directs the expression of a soluble glycoprotein and a vector which directs the expression of a fucosyltransferase enzyme.

### Claim 13 (depends on 12)

The method of claim 12 wherein the glycoprotein produced is soluble sialyl Lex containing leukosialin.

### Claim 14 (depends on 12)

The method of claim 12 wherein the mammalian cells are CHO cells.

### Claim 15 (depends on 1)

A method of inhibiting E-selectin mediated adhesion of carcinoma cells to endothelial cells comprising administering the antagonist of claim 1 to a subject.

### Claim 16

A method of inhibiting E-selectin mediated adhesion of carcinoma cells to endothelial cells comprising administering a sialyl Lex-glycoprotein, a sialyl Lex-glycolipid, or a sialyl Lex-chimeric glycoprotein to a subject.

### Claim 17

A method of determining the metastatic potential for a sample of carcinoma cells comprising determining the percentage of carcinoma cells which bind to E-selectin expressing cells.

### Claim 18 (depends on 17)

The method of claim 17, wherein said E-selectin expressing cells is selected from the group consisting of activated human endothelial cells, activated mouse endothelial cells, and CHO cells expressing E-selectin.

### Claim 19 (depends on 1)

A method of determining the metastatic potential for sample of carcinoma cells comprising determining whether an antagonist of claim 1 inhibits in a concentration dependent manner the adhesion of the carcinoma cell sample to E-selectin expressing cells.

### Claim 20 (depends on 19)

The method of claim 19, wherein the E-selectin expressing cells are selected from the group consisting of activated human endothelial cells, activated mouse endothelial cells, and CHO cells expressing E-selectin.
